Liver health and drug processing: a closer look at casdatifan

NCT ID NCT07751250

Not yet recruiting Knowledge-focused Sponsor: Arcus Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This study is testing how the body processes a single dose of casdatifan, an experimental drug, in people with moderate liver impairment compared to healthy volunteers. The goal is to see if liver function changes how the drug is absorbed and cleared from the body. Participants receive one 100 mg oral dose, and researchers measure drug levels in the blood over time. This information could help guide future dosing recommendations for patients with liver issues.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: casdatifan (AB521)
What this could lead to: If successful, this study could help determine the right dosing of casdatifan for people with liver problems, potentially making the drug safer and more effective for them.
What could go wrong: This is a small, early-stage study focused on drug processing, not on treating a disease. Results may not reflect real-world outcomes, and the drug could still have side effects or interact unpredictably with liver function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS HEPATIC IMPAIRMENT

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.